Home > Insider Trading > Filing (0001209191-21-027623)

Filing Details

Accession Number:: 0001209191-21-027623
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-20 18:59:28
Reporting Period:: 2021-04-16

Accepted Time:: 2021-04-20 18:59:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1741830	Kronos Bio Inc.	KRON	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1753644	Jakob Loven	C/O Kronos Bio, Inc. 1300 So. El Camino Real, Suite 300 San Mateo CA 94402		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-04-16	25,292	$20.84	1,344,962	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-16	7,870	$21.56	1,337,092	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-19	9,847	$20.25	1,327,245	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-19	4,157	$21.38	1,323,088	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-20	21,532	$20.10	1,301,556	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-20	19	$20.63	1,301,537	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

Shares were sold pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $21.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The securities are held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The Reporting Person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.23 to $21.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.87 to $20.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.87 to $21.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $20.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.